Free Trial

Pluri (PLUR) Competitors

Pluri logo
$5.01 -0.07 (-1.38%)
Closing price 07/15/2025 03:54 PM Eastern
Extended Trading
$5.14 +0.13 (+2.61%)
As of 07:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PLUR vs. CYBN, VYGR, IMAB, ACOG, LFVN, DERM, IPHA, ENTA, SPRO, and NVCT

Should you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Cybin (CYBN), Voyager Therapeutics (VYGR), I-Mab (IMAB), Alpha Cognition (ACOG), Lifevantage (LFVN), Journey Medical (DERM), Innate Pharma (IPHA), Enanta Pharmaceuticals (ENTA), Spero Therapeutics (SPRO), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry.

Pluri vs. Its Competitors

Cybin (NYSE:CYBN) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Pluri has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CybinN/AN/A-$57.88M-$3.88-1.92
Pluri$330K119.48-$20.89M-$5.53-0.91

Cybin has a net margin of 0.00% compared to Pluri's net margin of -2,563.29%. Cybin's return on equity of -37.58% beat Pluri's return on equity.

Company Net Margins Return on Equity Return on Assets
CybinN/A -37.58% -36.59%
Pluri -2,563.29%-4,191.91%-85.40%

In the previous week, Pluri had 1 more articles in the media than Cybin. MarketBeat recorded 1 mentions for Pluri and 0 mentions for Cybin. Pluri's average media sentiment score of 0.93 beat Cybin's score of -0.18 indicating that Pluri is being referred to more favorably in the news media.

Company Overall Sentiment
Cybin Neutral
Pluri Positive

Cybin has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

17.9% of Cybin shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 25.9% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cybin currently has a consensus price target of $85.00, suggesting a potential upside of 1,039.41%. Pluri has a consensus price target of $12.00, suggesting a potential upside of 139.52%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Pluri.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cybin
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
Pluri
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Cybin beats Pluri on 9 of the 16 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLUR vs. The Competition

MetricPluriMED IndustryMedical SectorNASDAQ Exchange
Market Cap$39.99M$2.96B$5.61B$9.29B
Dividend YieldN/A2.43%4.23%4.03%
P/E Ratio-0.9120.2228.5419.58
Price / Sales119.48299.17429.2495.01
Price / CashN/A43.1536.0257.93
Price / Book5.017.568.145.54
Net Income-$20.89M-$55.11M$3.24B$257.73M
7 Day Performance-9.07%3.81%0.18%-0.08%
1 Month Performance17.88%11.60%5.96%8.09%
1 Year Performance-14.36%-2.11%26.24%13.02%

Pluri Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PLUR
Pluri
3.2875 of 5 stars
$5.01
-1.4%
$12.00
+139.5%
-6.4%$39.99M$330K-0.91150Gap Down
High Trading Volume
CYBN
Cybin
2.4763 of 5 stars
$7.70
-2.2%
$86.00
+1,017.5%
N/A$176.13MN/A-1.7550
VYGR
Voyager Therapeutics
3.8881 of 5 stars
$3.15
+3.6%
$13.39
+325.1%
-65.6%$173.82M$80M-2.15100
IMAB
I-Mab
2.8477 of 5 stars
$2.13
+1.7%
$6.00
+182.4%
+28.8%$173.53M$3.89M0.00380Gap Down
ACOG
Alpha Cognition
1.727 of 5 stars
$10.75
-4.4%
$20.00
+86.0%
N/A$172.22MN/A-8.96N/APositive News
Gap Up
LFVN
Lifevantage
4.2759 of 5 stars
$13.43
-1.2%
$30.50
+127.1%
+102.6%$169.02M$200.16M19.46260News Coverage
Positive News
DERM
Journey Medical
2.4054 of 5 stars
$7.23
+1.8%
$9.50
+31.4%
+19.9%$165.55M$56.13M-18.2290Positive News
IPHA
Innate Pharma
2.6155 of 5 stars
$1.79
-1.6%
$11.00
+514.5%
-16.5%$165.00M$21.77M0.00220
ENTA
Enanta Pharmaceuticals
3.9272 of 5 stars
$7.77
-1.5%
$18.00
+131.7%
-60.2%$164.26M$67.64M-1.69160News Coverage
SPRO
Spero Therapeutics
3.9053 of 5 stars
$2.94
+1.2%
$5.00
+70.4%
+72.3%$164.10M$47.98M-2.29150
NVCT
Nuvectis Pharma
3.3056 of 5 stars
$7.82
-0.4%
$17.00
+117.5%
+24.5%$163.36MN/A-6.928Positive News

Related Companies and Tools


This page (NASDAQ:PLUR) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners